#Yasuko miyamoto kenshi miyamoto trial

In that study, FMD in the brachial artery was also measured in some of the subjects. The PROLOGUE study was a prospective multicenter study conducted to evaluate the inhibitory effect of a DPP-4 inhibitor on progression of atherosclerosis based on carotid artery intima-media thickness (IMT) assessed by ultrasonography over a 2-year follow-up period. However, the long-term effect of a DPP-4 inhibitor on FMD in patients with type 2 diabetes remains unclear. As for the relationship between a DPP-4 inhibitor and endothelial function in the conduit brachial artery assessed by flow-mediated vasodilation (FMD), a previous short-term study demonstrated that 6-week treatment with DPP-4 inhibitors, including sitagliptin and alogliptin, attenuated FMD, whereas other previous studies demonstrated that 12-week treatment with sitagliptin improved FMD in patients with type 2 diabetes. Sitagliptin, a DPP-4 inhibitor, has been demonstrated to significantly improve microvascular endothelial function assessed by the reactive hyperemia peripheral arterial tonometry index after 6В months in uncontrolled diabetic patients with coronary heart disease. The relationship between treatment with a DPP-4 inhibitor and endothelial function in patients with type 2 diabetes has been evaluated. The DPP-4 inhibitor prolongs the action of incretin hormones by inhibition of their breakdown and improves glycemic control through incretin hormone-induced decrease in glucagon levels and increase in endogenous insulin secretion in patients with type 2 diabetes.

These findings suggest that endothelial dysfunction is reversible and can be restored through an appropriate intervention in patients with type 2 diabetes.ДЄn orally administered dipeptidyl peptidase 4 (DPP-4) inhibitor is now available for treatment of type 2 diabetes. Several investigators have reported that lifestyle modification and pharmacological therapy, including antihyperglycemic agents, improve endothelial function in patients with type 2 diabetes.

Type 2 diabetes, an important risk factor for cardiovascular disease, is associated with endothelial dysfunction. In addition, it has been shown that endothelial function is an independent predictor of cardiovascular events.

#Yasuko miyamoto kenshi miyamoto trial

Trial registration: University hospital Medical Information Network (UMIN) Center: ID UMIN000004490Д®ndothelial dysfunction is the initial step in the pathogenesis of atherosclerosis and plays an important role in the development of this condition. Sitagliptin may be used without concern for an adverse effect on endothelial function in patients with type 2 diabetes. ConclusionsДЄdd-on sitagliptin to conventional antihyperglycemic drugs in patients with type 2 diabetes did not alter endothelial function in the conduit brachial artery measured by FMD during a 2-year study period. Although FMD had a tendency to increase from 4.3В В±В 2.4В % at baseline to 5.2В В±В 1.9В % after 12В months and 5.1В В±В 2.2В % after 24В months in the conventional group, there was no significant difference between FMD values at baseline and after 12 and 24В months (PВ =В 0.36 and 0.33, respectively). There was no significant difference between FMD values at baseline and after 12 and 24В months in the sitagliptin group (4.3В В±В 2.6 vs. HbA1c levels were significantly decreased after 12 and 24В months of treatment compared to baseline values in both groups (7.0В В±В 0.4 vs. Among the 463 participants in the PROLOGUE study, FMD was measured in 17 patients in the sitagliptin group and 18 patients in the conventional group at the beginning and after 12 and 24В months of treatment. In the PROLOGUE study, patients were randomly assigned to either add-on sitagliptin treatment (sitagliptin group) or continued conventional antihyperglycemic treatment (conventional group). As a sub-analysis of the PROLOGUE study, we evaluated the long-term effect of sitagliptin, a dipeptidyl peptidase 4 inhibitor, on endothelial function in the conduit brachial artery in patients with type 2 diabetes.